2026 MIDD Webinar Series | Design of a First-in-Human Study for a Brain-Penetrant Proteolysis-Targeting Chimera ARV-102 Using PKPD Modeling
Includes a Live Web Event on 04/08/2026 at 12:00 PM (EDT)
-
You must log in to register
- Non-member - $50
- Member - Free!
This webinar will focus on the PKPD models developed and used end-to-end to design and execute a Phase 1 study for a first brain-penetrant PROTAC ARV-102. Core PKPD models were developed using nonclinical data and included allometrically scaled PK parameters and animal-derived PD parameters for target engagement. Model simulations were used to select a dose range for the first in human study and the PKPD models were updated to refine the dose response. The iterative modeling-experimentation resulted in a successful Phase 1 study and illuminated important translational relationship of PROTAC PKPD between animals and humans.
The MIDD Webinar Series, coordinated by Yash Kapoor and Fulya Akpinar Singh, is a series of webinars focused on shaping the future of drug development and regulatory decision-making sponsored by the ISoP Education Committee. Topics range from MIDD approaches in regulatory submission to pharmacometrics topics that are at the core of model development.
Sergey Aksenov, PhD
Arnivas
Sergey Aksenov, a PhD in Physics from Moscow State University, is currently Head of Modeling and Simulation at Arvinas. He spearheads PKPD and pharmacometrics modeling for all PROTAC projects from discovery through confirmatory studies in neurology and oncology. His extensive experience includes translational and early-phase modeling for small molecules, biologics, and gene therapies at Novartis, and serving as Pharmacometrics Science Lead at AstraZeneca. Previously, he was a modeling and simulation scientist at Novartis, focusing on developing drug for neurology and ophthalmology diseases.
Complete
Next
Failed
Available
Locked